newsfilter
← Latest News
Business Wire·

Longboard Pharmaceuticals Completes Enrollment of Phase 1b/2a PACIFIC Study Evaluating LP352 for the Treatment of Developmental and Epileptic Encephalopathies

Enrolled 52 participants with Developmental and Epileptic Encephalopathies (DEEs) into the PACIFIC Study Participants have a broad range of DEEs including Lennox-Gastaut syndrome, Dravet syndrome, SCN2A-related